The discovery of incretin hormones’ role not only in regulating blood glucose levels but also in regulating body weight has been a breakthrough in the treatment of T2DM [67,68,69], as well as in managing obesity without concurrent glucose metabolism disorders [70,71]. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.